Sanofi and Regeneron’s Dupixent Wins New European Commission Approval

PARIS (Reuters) – Healthcare companies Sanofi and Regeneron said on Monday that their Dupixent product had won approval from the European Commission to treat eosinophilic esophagitis (EoE), which is a condition that damages the esophagus.

“This latest approval establishes Dupixent as the only targeted medicine specifically indicated for eosinophilic esophagitis in the European Union,” said George D. Yancopoulos, President and Chief Scientific Officer at Regeneron.

(Reporting by Sudip Kar-Gupta; Editing by Himani Sarkar)

Source: Read Full Article

Related posts:
  1. 10 symptoms acid reflux
  2. Parents of terminated foetus 'had no hope after test'
  3. Novel mechanical mechanism of metastatic cancer cells in substrates of different stiffness revealed
  4. Broomfield returning to Level Yellow on Colorado’s COVID-19 dial
  5. EXPLAINER: What does it mean for COVID-19 to be endemic?